Benitec Biopharma Inc.
BNTC
$12.77
$0.191.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -52.28% | 220.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.93% | 68.59% | |||
| Operating Income | 42.93% | -68.59% | |||
| Income Before Tax | 44.48% | -72.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.48% | -72.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.48% | -72.62% | |||
| EBIT | 42.93% | -68.59% | |||
| EBITDA | 42.96% | -68.67% | |||
| EPS Basic | 44.97% | -61.91% | |||
| Normalized Basic EPS | 44.98% | -61.85% | |||
| EPS Diluted | 44.97% | -61.91% | |||
| Normalized Diluted EPS | 44.98% | -61.85% | |||
| Average Basic Shares Outstanding | 0.88% | 6.63% | |||
| Average Diluted Shares Outstanding | 0.88% | 6.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||